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Malignant neoplasms of the kidney and ureter comprise around
2% of adult cancers in England and Wales, some 5000 new cases a
year. Cancers of the kidney account for some 90% of upper urinary
tract malignancies. They are analysed together here, and will often
be referred to as kidney cancer for brevity. Incidence is two to
three times higher in Europe and North America than in Africa,
Asia or Latin America (Ferlay et al, 2004).
Cancers of the kidney and ureter are twice as common in men.
They are uncommon before the age of 50, with age-specific
incidence rising steeply above that age, especially in men.
Incidence rates increased by about 50% in England and Wales to
10 and 6 per 100000 per year in men and women, respectively,
between the mid-1980s and 1999 (Quinn et al, 2001). There was no
systematic difference between socioeconomic groups in incidence
or in incidence trends during the period 1986–1999 (data not
shown). Mortality rates for kidney cancer in England and Wales
have remained fairly stable over the last decade (Quinn et al, 2001).
Renal cell adenocarcinoma typically accounts for 80% or more
of renal cancers, and urothelial (transitional cell) carcinoma of the
renal pelvis and ureter accounts for most of the remainder (Harris
and Simons, 2004). Wilms’ tumour (nephroblastoma) is the most
common renal tumour in children, but it is very rare in adults (less
than 0.2 per million per year) (Mitry et al, 2006).
Obesity, smoking and hypertension are associated with an
increased risk of renal cell carcinoma (Lipworth et al, 2006).
Smoking is also a risk factor for urothelial carcinoma of the renal
pelvis and ureter (McLaughlin et al, 1992), as is occupational
exposure to petrochemicals.
The triad of flank pain, abdominal mass and haematuria has
been the basis of clinical diagnosis, but incidental diagnosis during
abdominal imaging has become more common, and it may
underlie part of the increase in recorded incidence. Non-specific
symptoms and the retroperitoneal location of the kidneys make
early clinical diagnosis difficult. Less than half of patients have
disease confined to the kidney at diagnosis, and a quarter present
with metastatic disease, often in lung or bone. Nephrectomy is the
main treatment for renal carcinoma, with interleukin-2 and
interferon for advanced disease (Harris and Simons, 2004).
We analysed the survival of 49721 adults (63% men) who were
diagnosed with a first, primary, invasive neoplasm of the kidney or
ureter in England and Wales during the 14-year period 1986–1999
and followed up to the end of 2001, about 81% of the 61189
patients eligible for analysis. Some 12% of patients were excluded
from analysis because their recorded survival was zero (date of
diagnosis same as the date of death): most of these will have been
registered from a death certificate only (DCO), but in these data,
they could not be reliably distinguished from patients with true
zero survival. Other patients were excluded because the kidney
cancer was not their first primary cancer (4.6%), or because their
vital status was unknown on 5 November 2002, when the data were
extracted for analysis (1.5%).
Renal cell carcinoma accounted for about 87% of kidney cancers
analysed. Around 10% were transitional cell carcinomas of the
renal pelvis or ureter, and the remainder were coded to other or
unspecified urinary organs (data not shown).
SURVIVAL TRENDS
Relative survival from kidney cancer at 1 year was 58% for men
and 54% for women diagnosed during 1986–1990, rising steadily
to 65 and 61%, respectively, for those diagnosed during 1996–1999
(Table 1, Figure 1). For patients diagnosed during 1996–1999,
5-year survival had reached 46% in men and women. These
changes represent a statistically significant deprivation-adjusted
rate of increase of about 3% every 5 years for 1-year survival and
4–5% for 5-year survival. Improvements were slightly more
marked in longer-term survival.
Short-term survival predictions, based on hybrid analysis
(Brenner and Rachet, 2004) of the conditional probabilities of
survival actually observed among men alive at some point during
2000–2001, suggest that survival up to 10 years after diagnosis will
continue to improve, but somewhat more slowly, reaching 62–65%
at 1 year, 46–47% at 5 years and 39–42% at 10 years, for patients
diagnosed in 2000–2001 (Table 1, Figure 1).
DEPRIVATION
Among men, relative survival was systematically higher in
more affluent groups, both at 1 year and at 5 years after
diagnosis. The fitted difference in relative survival at 5 years
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(the deprivation gap) widened from  3% for those diagnosed in
1986–1990 to  6% for those diagnosed during 1996–1999, a
statistically significant change of about  2% every 5 years (Table 2,
Figure 2).
For women, in contrast, the deprivation gap in survival at both 1
and 5 years narrowed steadily during the 1990s, and was null or
non-significant for those diagnosed during 1996–1999. Figure 2
shows the flattening of the gradient in 5-year survival.
Short-term predictions from hybrid analysis suggest that
the deprivation gap in survival up to 5 years is not likely
to increase further in the near future, and may fall slightly for
men (Table 2).
COMMENT
Survival from kidney cancer in England and Wales has increased
steadily for both sexes during the last three decades. Relative
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 58.3 (57.2, 59.3) 60.9 (60.0, 61.9) 64.5 (63.5, 65.4) 2.6** (0.7, 4.6) 64.9 (63.5, 66.2)
Women 53.5 (52.1, 54.9) 56.2 (55.0, 57.4) 61.2 (60.0, 62.5) 3.0* (0.4, 5.5) 62.0 (60.2, 63.7)
5 years Men 40.1 (38.9, 41.2) 42.8 (41.7, 43.8) 46.1 (44.8, 47.4) 4.5** (2.1, 6.8) 46.9 (45.3, 48.4)
Women 35.9 (34.5, 37.4) 39.7 (38.4, 41.0) 45.7 (44.1, 47.3) 3.7* (0.8, 6.7) 46.3 (44.3, 48.3)
10 years Men 33.0 (31.8, 34.3) 35.6 (34.3, 37.0) 4.4 ( 0.2, 9.0) 39.4 (37.6, 41.2)
Women 30.5 (29.0, 32.0) 35.4 (33.9, 36.9) 5.9* (0.4, 11.4) 41.9 (39.7, 44.1)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival
estimated with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%)
by sex and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001.
Survival from cancers of the kidney and ureter
S Westlake et al
S94
British Journal of Cancer (2008) 99(S1), S93–S95 & 2008 Cancer Research UKsurvival at 5 years for patients diagnosed in 1971–1975 was only
30–31%, compared with around 46% for those diagnosed in the
late 1990s. The pace of increase in survival has also improved,
from around 3% every 5 years during the 1970s and 1980s
(Coleman et al, 1999) to around 5% every 5 years in the 1990s, as
seen in the data reported here.
Cancer of the kidney is unusual in that it is one of the few
cancers for which men have tended to have a small survival
advantage over women. Socioeconomic inequalities in survival are
notably more marked among men, however, and they
increased during the 1990s, whereas those for women have
virtually disappeared. The explanation for these patterns is
unclear.
Patients excluded from analysis as DCO cases may be biased
with respect to survival (Berrino et al, 1995a), but the proportion
of DCO cases excluded from analysis was the same in all categories
of deprivation throughout the period 1986–1999 in both sexes
(data not shown). The socioeconomic differences in survival, and
the opposite trends in men and women, are thus unlikely to have
been affected by these exclusions.
Five-year survival among patients diagnosed with kidney cancer
in England up to the mid-1990s was among the lowest in Europe
(Berrino et al, 1995b; Berrino et al, 1999; Berrino et al, 2003). Most
of the improvement in survival in England and Wales occurred
during the late 1990s, after the period of diagnosis covered by the
EUROCARE-3 study (1990–1994).
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  5.4** ( 8.5,  2.4)  7.9** ( 10.5,  5.2)  4.1** ( 6.9,  1.3) 0.7 ( 1.5, 2.9)  2.7 ( 6.7, 1.3)
Women  4.0 ( 7.9, 0.0)  0.6 ( 4.2, 2.9)  1.4 ( 5.0, 2.3) 1.3 ( 1.5, 4.2)  1.9 ( 7.0, 3.3)
5 years Men  2.7 ( 6.1, 0.6)  6.0** ( 9.0,  3.1)  5.8** ( 9.5,  2.0)  1.7 ( 4.3, 0.9)  2.7 ( 7.3, 1.8)
Women  3.0 ( 7.1, 1.2)  1.4 ( 5.2, 2.3) 0.0 ( 4.6, 4.6) 1.6 ( 1.6, 4.8) 2.4 ( 3.3, 8.1)
10 years Men  1.0 ( 4.5, 2.6)  3.4 ( 7.2, 0.4)  2.4 ( 7.6, 2.8)  1.6 ( 6.7, 3.5)
Women  1.3 ( 5.6, 3.0)  2.7 ( 7.1, 1.7)  1.4 ( 7.5, 4.7) 0.5 ( 5.8, 6.8)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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